/Intuitive%20Surgical%20Inc%20location%20sign-by%20Sundry%20Photography%20via%20iStock.jpg)
With a market cap of $191.3 billion, Intuitive Surgical, Inc. (ISRG) designs, manufactures, and markets advanced robotic systems that support minimally invasive surgeries. Its flagship products include the da Vinci Surgical System and the Ion endoluminal system, which enhance surgical precision and expand diagnostic capabilities. The Sunnyvale, California-based company is expected to announce its fiscal Q2 2025 earnings results on Thursday, July 17.
Ahead of this event, analysts are expecting ISRG to report a profit of $1.52 per share, up 3.4% from $1.47 per share in the year-ago quarter. The company has exceeded Wall Street's bottom-line estimates in the past four quarters. In Q1 2025, Intuitive Surgical surpassed the consensus EPS estimate by 3.7%.
For fiscal 2025, analysts expect the surgical robot maker to report EPS of $6.23, down 3.9% from $6.48 in fiscal 2024. However, EPS is expected to rebound and grow nearly 18% year-over-year to $7.35 in fiscal 2026.
ISRG stock has climbed 19.9% over the past year, outperforming the S&P 500 Index's ($SPX) 12.6% gain and the Health Care Select Sector SPDR Fund's (XLV) 8.2% decline over the same period.
Shares of Intuitive Surgical rose 1.9% following its Q1 2025 results on Apr. 22, primarily because the company beat analysts' expectations, reporting adjusted EPS of $1.81 and revenue of $2.3 billion. The company placed 367 da Vinci systems, including 147 of its next-generation da Vinci 5 systems. Additionally, the global procedure growth of 17% and a 15% increase in the installed base to 10,189 systems reinforced investor confidence.
Analysts' consensus rating on Intuitive Surgical stock is cautiously optimistic overall, with a "Moderate Buy" rating. Out of 28 analysts covering the stock, 19 recommend a "Strong Buy," two have a "Moderate Buy" rating, six give a "Hold" rating, and one "Strong Sell." This configuration is slightly more bullish than three months ago, with 18 analysts suggesting a "Strong Buy."
As of writing, ISRG is trading below the average analyst price target of $589.92.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
